NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	pulmonary arterial hypertension
Date of first enrollment	03/03/2014
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : QTI571 INN of investigational material : imatinib Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigational material : QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day

Outcome(s)

Primary Outcome	Serious Adverse Events All Serious Adverse events will be evaluated and reported for all participants receiving QTI571
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	1. Patient is receiving QTI571 for the treatment of PAH and is currently enrolled in the extension study (A2301E1) in Japan. 2. Patient is currently benefitting from the treatment with QTI571 in the opinion of the investigator.
Exclude criteria	1. Patient has been permanently discontinued from QTI571 study treatment in the parent study. 2. Concomitant use of oral vitamin K antagonist medication.